Crescita Therapeutics (Crescita Therapeutics) Cash-to-Debt : 7.49 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Crescita Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 7.49.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Crescita Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Crescita Therapeutics's Cash-to-Debt or its related term are showing as below:

CRRTF' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.62 Med: 5.55 Max: No Debt
Current: 7.48

During the past 10 years, Crescita Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 1.62. And the median was 5.55.

CRRTF's Cash-to-Debt is ranked better than
74.81% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.945 vs CRRTF: 7.48

Crescita Therapeutics Cash-to-Debt Historical Data

The historical data trend for Crescita Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Crescita Therapeutics Cash-to-Debt Chart

Crescita Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

5.99

11.61

3.95

5.11

7.49

Crescita Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															5.11	6.78	7.23	7.65	7.49

Competitive Comparison of Crescita Therapeutics's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescita Therapeutics's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's Cash-to-Debt falls into.

Crescita Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Crescita Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.995	/	(0.327	+	0.607)
	=	7.49

Crescita Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.995	/	(0.327	+	0.607)
	=	7.49

Crescita Therapeutics (OTCPK:CRRTF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Crescita Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescita Therapeutics (Crescita Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (OTCPK:CRRTF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CTX:Canada

Address

2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3

Website

https://www.crescitatherapeutics.com

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.